Why ASX private health shares aren't as good as they look

Here's why I don't like the future prospects of ASX private health stocks like Medibank Private Ltd (ASX: MPL)

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

From my humble observations, Australians seem to enjoy a love/hate relationship with private health insurance. It's always nice flashing your card when you visit the dentist or physio, but paying those weekly or monthly premiums is a bit of a hassle (to put it mildly).

What's more, private health premium costs are one of those things that just seem to keep on rising – usually well above inflation and the cost of living as well.

So with that in mind, you would think private health is a ripe place to invest these days. The sector enjoys widespread use and acceptance as a 'backup' to the publicly funded Medicare. Not only that, there are significant government incentives for individuals (particularly on higher incomes) to take out private health insurance – along with penalties for those who don't.

Most companies don't enjoy that kind of public assistance – in fact, having the government herd customers into your arms is something most businesses can only dream of. Reviewing the performance of the ASX's 2 largest private health insurers, it looks on first glance as though private health is a no-brainer.

Medibank Private Ltd (ASX: MPL) shares have only been on the public markets since its privatisation in 2014 at around $2 per share. Today, MPL shares are going for $3.36 (at the time of writing) and come with a 3.88% dividend yield. A dividend yield that has been steadily increasing since 2014 to boot!

It's a similar story with NIB Holdings Limited (ASX: NHF). NHF shares were asking around $1.30 10 years ago, but today will set you back $6.92, with a 3.89% dividend yield. NIB's dividend payouts have also been steadily increasing over the past decade.

The problem with private health

Before you get the cheque book out, I think it's worth noting that past performance is no indication of the future. As a matter of fact, I believe that things aren't looking so rosy from here.

We have a rapidly ageing population in Australia, which means that over time there will be less healthy, younger people to pay for the higher medical needs of the older generations.

That means rising premiums.

Rising premiums in turn mean there is less incentive for younger people to take out the health insurance in the first place. This has the potential to become a vicious cycle for the fund providers, if it isn't happening already.

Foolish takeaway

Whilst I love both Medibank's and NIB's management and past performance, I think there are significant structural issues for this space as a whole going forward. These issues make me disinclined to pursue this industry for my own portfolio – at least until I can see a clearer path towards the system's sustainability.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »